NASDAQ · Biotechnology · USD
XTL Biopharmaceuticals Ltd. (XTLB) Stock Analysis
XTL Biopharmaceuticals Ltd. (XTLB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
XTLB Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.87
- Previous Close
- $1.94
- Day's Range
- 1.87–1.94
- 52-Week Range
- 1.86–5.64
- Volume
- 4.24K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.43
Valuation
- Market Cap
- $4.60M
- P/E Ratio
- unprofitable
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 2.27
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.36
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$6.97M
- Shares Outstanding
- 2.46M
- 1-Year Return
- −63.76%
Dividend and dates
- Avg Volume
- 7.74K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, XTLB closed at $1.87, −63.76% over 1 year.
XTL Biopharmaceuticals Ltd. (XTLB) has a market capitalization of $4.60M.
In fiscal 2025, XTLB reported revenue of $0.00.
XTLB Stock Return by Calendar Year
XTL Biopharmaceuticals Ltd. (XTLB) 10-year return: what $10,000 became
- 1 year
- $10,000 $3,624
- −63.76%
- 5 years
- $10,000 $1,227
- −87.73%
- 10 years
- $10,000 $995
- −90.05%
If you had invested $10,000 in XTL Biopharmaceuticals Ltd. (XTLB) 10 years ago, at the close on October 21, 2016, it would have been worth $995 at the close on October 21, 2026: −90.05% in total, −20.61% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −19.40% |
| 2025 | −71.43% |
| 2024 | +100.99% |
| 2023 | −16.53% |
| 2022 | −56.32% |
| 2021 | −8.58% |
| 2020 | +121.17% |
| 2019 | −20.81% |
| 2018 | −24.45% |
| 2017 | −27.30% |
| 2016 (partial year) | −47.06% |
As of October 21, 2026.
XTLB Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$6.97M | — |
| 2024 | $0.00 | −$1.03M | — |
| 2023 | $0.00 | −$1.78M | — |
| 2022 | $0.00 | −$1.35M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | −$1.38M | −$6.97M | — |
| 2024 | $0.00 | $0.00 | −$775.00K | −$1.03M | — |
| 2023 | $0.00 | $0.00 | −$765.00K | −$1.78M | — |
| 2022 | $0.00 | $0.00 | −$880.00K | −$1.35M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B